Data Protection, Integrity, & Quality Assurance


Improving Transparency to Build Trust in Real-World Secondary Data Studies - Real-World Evidence Transparency Initiative

Published Sep 2020

Citation

Orsini, LS, Berger ML, Crown W. et al.  Improving transparency to build trust in real-world secondary data studies for hypothesis testing—why, what, and how: recommendations and a road map from the Real-World Evidence Transparency Initiative. Value Health. 2020; 23(9):1128-1136.  

Abstract

Real-world data (RWD) and the derivations of these data into real-world evidence (RWE) are rapidly expanding from informing healthcare decisions at the patient and health system level to influencing major health policy decisions, including regulatory approvals and coverage. Recent examples include the approval of palbociclib in combination with endocrine therapy for male breast cancer and the inclusion of RWE in the label of paliperidone palmitate for schizophrenia.

This interest has created an urgency to develop processes that promote trust in the evidence-generation process. Key stakeholders and decision-makers include patients and their healthcare providers; learning health systems; health technology assessment bodies and payers; pharmacoepidemiologists and other clinical researchers, and policy makers interested in bioethical and regulatory issues. A key to optimal uptake of RWE is transparency of the research process to enable decision-makers to evaluate the quality of the methods used and the applicability of the evidence that results from the RWE studies.


Reproducibility and Replicability


Improving Transparency to Build Trust in Real-World Secondary Data Studies - Real-World Evidence Transparency Initiative

Published Sep 2020

Citation

Orsini, LS, Berger ML, Crown W. et al.  Improving transparency to build trust in real-world secondary data studies for hypothesis testing—why, what, and how: recommendations and a road map from the Real-World Evidence Transparency Initiative. Value Health. 2020; 23(9):1128-1136.  

Abstract

Real-world data (RWD) and the derivations of these data into real-world evidence (RWE) are rapidly expanding from informing healthcare decisions at the patient and health system level to influencing major health policy decisions, including regulatory approvals and coverage. Recent examples include the approval of palbociclib in combination with endocrine therapy for male breast cancer and the inclusion of RWE in the label of paliperidone palmitate for schizophrenia.

This interest has created an urgency to develop processes that promote trust in the evidence-generation process. Key stakeholders and decision-makers include patients and their healthcare providers; learning health systems; health technology assessment bodies and payers; pharmacoepidemiologists and other clinical researchers, and policy makers interested in bioethical and regulatory issues. A key to optimal uptake of RWE is transparency of the research process to enable decision-makers to evaluate the quality of the methods used and the applicability of the evidence that results from the RWE studies.

Full Content

Download PDF

Related Content


All Real World Data & Information Systems Reports


Please Note: Reports are in reverse chronological order.
Improving Transparency to Build Trust in Real-World Secondary Data Studies - Real-World Evidence Transparency Initiative

Published Sep 2020

Citation

Orsini, LS, Berger ML, Crown W. et al.  Improving transparency to build trust in real-world secondary data studies for hypothesis testing—why, what, and how: recommendations and a road map from the Real-World Evidence Transparency Initiative. Value Health. 2020; 23(9):1128-1136.  

Abstract

Real-world data (RWD) and the derivations of these data into real-world evidence (RWE) are rapidly expanding from informing healthcare decisions at the patient and health system level to influencing major health policy decisions, including regulatory approvals and coverage. Recent examples include the approval of palbociclib in combination with endocrine therapy for male breast cancer and the inclusion of RWE in the label of paliperidone palmitate for schizophrenia.

This interest has created an urgency to develop processes that promote trust in the evidence-generation process. Key stakeholders and decision-makers include patients and their healthcare providers; learning health systems; health technology assessment bodies and payers; pharmacoepidemiologists and other clinical researchers, and policy makers interested in bioethical and regulatory issues. A key to optimal uptake of RWE is transparency of the research process to enable decision-makers to evaluate the quality of the methods used and the applicability of the evidence that results from the RWE studies.

Full Content

Download PDF

Related Content

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×